Media Coverage Archive 2018

Media Coverage

Media Coverage Archive 2018

This page contains a listing of news items featuring Fred Hutch.  Older items may be located in the archive to the left.

Coloradoan, Sept. 27, 2018
Dr. Fred Applebaum, the Hutch’s executive vice president and deputy director, commented about the recipient of the first unrelated donor transplant, that eventually led to the national match registry.
KIRO-TV, Sept. 27, 2018
This story previewed a walk-a-thon organized by Seattle’s Dick’s Drive-In to benefit Fred Hutch cancer research.
KIRO-TV, Sept. 27, 2018
This story focused on a $300k grant Dr. Roland Walter received from Hyundai. It included interviews with Dr. Walter & a pediatric cancer patient.
OncLive, Sept. 26, 2018
OncLive reported on the Science Summit on Hematologic Malignancies with faculty affiliated with Fred Hutch and the Seattle Cancer Care Alliance.
The ASCO Post, Sept. 26, 2018
In a video, Fred Hutch’s Dr. Jerald Radich discussed therapeutic strategies for chronic myeloid leukemia.
U.S. News & World Report, Sept. 26, 2018
Dr. Scott Ramsey, director of Fred Hutch’s health economics group, talked about a partnership between the Hutch and Microsoft, using artificial intelligence technology to help cancer patients detect early, subtle signs of complications in an effort to improve patient health while lowering costs.
GeekWire, Sept. 24, 2018
Fred Hutch researchers Drs. Aude Chapuis and Kelly Paulson were quoted about their study identifying a potential cause for relapse in patients treated with immunotherapy for Merkel cell carcinoma, a skin cancer.
Fierce Biotech, Sept. 24, 2018
This article on an experimental treatment to counter severe side effects that can occur with CAR T-cell immunotherapy mentions Fred Hutch research pursuing ways to predict severity and to create safer treatments.
Fierce Biotech, Sept. 21, 2018
This story about a new study using immunotherapy to eradicate HIV “reservoirs” mentions a Fred Hutch pre-clinical study in which a gene-editing technique caused virus reservoirs to shrink.
Oncology Times, Sept. 20, 2018
This article in a resource for clinicians traces the history of CAR T-cell immunotherapy for cancer treatment and credits numerous researchers, including Dr. Stan Riddell and colleagues at the Hutch.
MedicalResearch.com, Sept. 14, 2018
Fred Hutch’s Dr. Nina Salama was interviewed about her research linking a strain of Helicobacter pylori to stomach cancer in a group of patients in China.
Medical News Today, Sept. 13, 2018
This article mentions research by Fred Hutch’s Dr. Nina Salama and her team that identified a strain of Helicobacter pylori associated with stomach cancer.
Cancer Today, Sept. 13, 2018
This story summarized a study led by Dr. Joe Unger focused on outcomes for rural vs. urban cancer patients.
U.S. News & World Report, Sept. 12, 2018
Dr. Hans-Peter Kiem, director of Fred Hutch’s stem cell and gene therapy program, is featured in this article about CRISPR, a new gene-editing tool.
KIRO-FM, Sept. 12, 2018
This historical feature about Fred Hutchinson's baseball career includes comments from Dr. Fred Appelbaum on how naming the Center in Hutchinson's honor keeps it tied to the Seattle community and culture.
The Scientist, Sept. 6, 2018
Fred Hutch gastroenterology researcher Dr. Neelendu Dey commented on a study published by scientists in Israel on the effects of probiotics.
CancerNetwork, Sept. 5, 2018
Fred Hutch researcher Alex Salter is quoted in this Cancer Network article about T-cell signaling in chimeric antigen receptor (CAR) T-cell immunotherapy. His Fred Hutch study investigated molecules called costimulatory domains that are instrumental in the way CARs give instructions to T cells.
OncLive, Aug. 31, 2018
This story summarizes a study led by Fred Hutch researcher and SWOG biostatistician Dr. Joseph Unger about cancer disparities between urban and rural patients.
Journal of Clinical Pathways, Aug. 30, 2018
Fred Hutch’s Dr. Gary Lyman was interviewed in this Q&A on the regulation and use of a class of drugs called biosimilars in cancer care.
FierceBiotech, Aug. 28, 2018
FierceBiotech mentions a Fred Hutch study on how two chimeric antigen receptor (CAR) T-cell designs attack cancer.
CNN, Aug. 25, 2018
In this CNN story, Fred Hutch’s Dr. Eric Holland said studies using targeted cancer therapies against glioblastoma have been unexpectedly disappointing.
Reuters, Aug. 23, 2018
This story about new research on heaving drinking and aggressive prostate cancer quoted Fred Hutch’s Dr. Anne McTiernan, a cancer-prevention expert who was not involved in the study.
HealthLeaders, Aug. 23, 2018
This story summarizes a study led by Fred Hutch researcher and SWOG biostatistician Dr. Joseph Unger about cancer disparities between urban and rural patients.
ASCO Post, Aug. 22, 2018
This ASCO Post article provided an overview of the methodology and results of a study co-led by the Hutch’s Dr. Joseph Unger on health disparities between rural and urban cancer patients.
GeekWire, Aug. 21, 2018
Lead author Alex Salter and senior author Dr. Stanley Riddell were quoted in this GeekWire article about a Fred Hutch study on co-stimulatory domain, a component of chimeric antigen receptor (CAR) T cells. Riddell said the researchers learned how the receptors are signaling, and the new insights may provide important direction for future work.
STAT, Aug. 21, 2018
Lead author Alex Salter and senior author Dr. Stanley Riddell were quoted in this STAT article about a Fred Hutch study on co-stimulatory domain, a component of chimeric antigen receptor (CAR) T cells. Different co-stimulatory domains might affect safety and efficacy of these immunotherapies.
American Journal of Managed Care,
A healthcare trade publication puts the CAR T-cell signaling study into context with approved CAR T-cell therapies and how to improve them.
Becker’s Hospital Review, Aug. 20, 2018
This story summarizes a study led by Fred Hutch researcher and SWOG biostatistician Dr. Joseph Unger about cancer disparities between urban and rural patients.
Oregon Public Broadcasting, Aug. 20, 2018
Dr. Joseph Unger, a Fred Hutch researcher, is quoted about a study he co-led on survival rate disparities between rural and urban cancer patients.
Moms.com, Aug. 20, 2018
Dr. Holly Harris' study on links between endometriosis and childhood abuse was the focus of this story.
HealthDay, Aug. 17, 2018
Dr. Joseph Unger, a Fred Hutch researcher, is quoted in this UPI/HealthDay News story about a study he co-led on survival rate disparities between rural and urban cancer patients. This story was syndicated and shared via multiple outlets.
Prevention, Aug. 16, 2018
Fred Hutch’s Dr. William Grady was interviewed for this article about pancreatic cancer.
Prevention, Aug. 15, 2018
Fred Hutch’s Dr. Jennifer Specht is quoted in this story about the various types of breast cancer.
Healthline, Aug. 15, 2018
Fred Hutch’s Dr. Holly Harris is quoted in this story about a study she authored on the associated between childhood physical and sexual abuse and adulthood endometriosis.
KCPQ-TV/Q13 FOX, Aug. 15, 2018
Fred Hutch research and the Northwest Metastatic Breast Cancer Conference were highlighted in this story about a man who has metastatic breast cancer.
The Daily Herald (Everett, Washington), Aug. 15, 2018
Fred Hutch's Science Education Partnership program was featured in this story, focusing on a new training program for high school sophomores and juniors
Bustle, Aug. 15, 2018
Fred Hutch guidance is mentioned in this article written by a woman who tested positive for BRCA2, a gene mutation that increases risk of developing breast and ovarian cancer.
Scientific American, Aug. 14, 2018
This story cites new research led by Fred Hutch focused on the ideal age for men and women to receive their first colonoscopy screening.
The Wall Street Journal, Aug. 12, 2018
Research at Fred Hutch and the University of Washington is mentioned in this story about inherited gene mutations and the cancer risk for men.
Puget Sound Business Journal, Aug. 11, 2018
Lydig Construction’s efforts to raise money for Fred Hutch research was mentioned in this article about why the company is ranked among Washington’s 100 best workplaces.
KING-TV, Aug. 10, 2018
KING-TV newscasts provided extensive coverage of Fred Hutch’s Obliteride biking/walking fundraising event, including numerous stories about participants and their inspiration and motivation. This story profiled Smeeta Hirani and how she learned to ride a bike to honor her father, who died from lung cancer.
KING-TV, Aug. 10, 2018
Lauren Nudo, a stage 4 colon cancer patient, is featured in this story about the importance of awareness and raising money for cancer research.
KIRO-TV, Aug. 9, 2018
Fred Hutch’s “Pathway Explorers” program, a summer boot camp to get more high school students interested in science, was profiled in this KIRO-TV story.
KIRO-FM: “The Ron and Don Show”, Aug. 9, 2018
Fred Hutch’s Obliteride biking/walking fundraising event was the focus of “The Ron and Don Show.” The hosts interviewed the event’s organizer and a participant about the importance of fundraising.
GeekWire, Aug. 8, 2018
This GeekWire article and podcast weaves together Fred Hutch expertise in bone marrow transplantation and newer cell therapies, such as CAR T. The Hutch’s Dr. Stan Riddell and Dr. David Maloney talk about how CAR T-cell immunotherapy and how it was considered a crazy idea in the 1980s.
STAT, Aug. 8, 2018
Fred Hutch’s Dr. Nancy E. Davidson is quoted in this story about a new study that found cancer cell lines can evolve and produce different results in identical experiments.
Philadelphia Inquirer, Aug. 8, 2018
Dr. Robert Pierce, a pathologist at the Fred Hutchinson Cancer Research Center and an immunotherapy expert in checkpoint inhibitors, provided an expert comment on a new study examining cancer's ability to manipulate the immune system and protect itself from treatments.
KGTV, Aug. 7, 2018
Fred Hutch’s Dr. Nancy Davidson is mentioned in this story as a speaker at the 20th annual V Foundation Wine Celebration to raise money for cancer research.
Contemporary OB/GYN, Aug. 6, 2018
Fred Hutch’s Dr. Holly Harris is quoted in this story about a study she authored on the association between childhood physical and sexual abuse and adulthood endometriosis.
KIRO-TV, Aug. 4, 2018
This story featured a group of Obliteride participants who agreed to fundraise for Fred Hutch in memory of Jeanette Woldseth, the first professional female firefighter in Washington.
STAT: The Readout Loud, Aug. 2, 2018
Luke Timmerman, the Seattle bioscience writer who scaled Mount Everest to raise funds for Fred Hutch cancer research is interviewed in this podcast and shared his experience.
Reuters, July 25, 2018
Fred Hutch’s Dr. Holly Harris is quoted in this story about a study she authored on the association between childhood physical and sexual abuse and adulthood endometriosis.
The ASCO Post, July 25, 2018
Fred Hutch’s Dr. Gary Lyman is quoted in this article announcing that the American Society of Clinical Oncology now accepts certain integrative therapies for patients and survivors of breast cancer. Lyman was co-chair of the ASCO panel reviewing the clinical practice guidelines.
The ASCO Post, July 25, 2018
In an article on the future of biosimilars, biologic agents that are highly similar but not identical to approved reference biologic agents, The ASCO Post quoted extensively from a recent article by the Hutch’s Dr. Gary Lyman and colleagues in The New England Journal of Medicine.
OncLive, July 25, 2018
Fred Hutch’s Dr. Paul Nghiem discussed immunotherapy for the treatment of Merkel cell carcinoma in this video interview.
KIRO-TV, July 24, 2018
Jean Nelson, a top-10 “Base 2 Space” stair-climber in last year’s event, is among those who got to climb to the top of the Space Needle mast. “Base 2 Space” participants ascend the 832 stairs of Seattle’s landmark, and the latest event raised more than $860,000 for Fred Hutch research.
Targeted Oncology, July 24, 2018
Fred Hutch’s Dr. David Maloney describes the clinical trials work being done at the Bezos Family Immunotherapy Clinic. Researchers are looking at chimeric antigen receptor (CAR) T cells in a variety of settings.
KNKX-FM, July 23, 2018
This story profiles the experience of two high school science teachers, participating in Fred Hutch’s Science Education Partnership. The program pairs science teachers with Fred Hutch researchers to gain skills and expertise to bring into the classroom.
Healio, July 23, 2018
This article about a promising experimental therapy for patients with advanced head and neck squamous cell carcinoma mentions the groundbreaking work of the late Dr. Eduardo Mendez, a physician-scientist at Fred Hutch.
570 KVI, July 23, 2018
This story details radio host John Carlson’s efforts to raise money for cancer research at Fred Hutch by climbing Mt. St. Helens.
Blasting News, July 22, 2018
A study led by Fred Hutch's Dr. Holly Harris about the links between endometriosis and childhood abuse was the focus of this story.
Forbes, July 19, 2018
This article on early life trauma mentions a recent Fred Hutch study showing that women who were abused as children are at higher risk for endometriosis, likely mediated by stress hormones and increased inflammation.
Thatbreastcancer.com, July 19, 2018
In the first of a four-part series of interviews at the San Antonio Breast Cancer Symposium, Fred Hutch’s Dr. Julie Gralow discussed clinical trials of several new therapies showing promise for improved longevity among metastatic breast cancer patients.
OncLive, July 18, 2018
An OncLive video and article featured Fred Hutch’s Dr. David Maloney discussing responses, toxicities and recurrence rates of three chimeric antigen receptor (CAR) T-cell therapy products for treating non-Hodgkin lymphoma.
Timmerman Report, July 17, 2018
Luke Timmerman, the Seattle bioscience writer whose expedition to climb Mount Everest garnered extensive media coverage and raised $339,000 for cancer research at Fred Hutch, shared lessons he learned from the two-month odyssey.
OncLive, July 17, 2018
A Fred Hutch study on costs and quality of cancer care among 27 participating cancer clinics in Washington state was featured in this story.
OncLive, July 16, 2018
Dr. Todd A. Yezefski, a Fred Hutch senior fellow, discussed a Fred Hutch-led study comparing treatment, cost and outcomes of colorectal cancer patients in Washington state and British Columbia.
The Vancouver Sun, July 12, 2018
The Vancouver Sun is the latest media outlet to cover recent Fred Hutch research showing that colon cancer patients north of the border pay half as much as those in Washington state, but treatments and outcomes are similar.
The Seattle Times, July 11, 2018
Fred Hutch researchers are working with the city of Seattle to investigate whether firefighters at Station 31 have higher cancer rates than those at other stations. Designed to answer longstanding questions, the study is expected to conclude by summer 2019.
OncLive, July 10, 2018
Dr. Evan Yu, a member of Fred Hutch’s Institute for Prostate Cancer Research, was interviewed about new treatments with promising survival statistics for patients with prostate cancer that has developed resistance to standard hormone therapy, called castration-sensitive prostate cancer.
The ASCO Post, July 10, 2018
“Clinical trials are difficult, and they cost a lot of money,” said Dr. Aude Chapuis, a Fred Hutch researcher investigating T-cell therapy. She received the 2010 Young Investigator Translational Research Award, jointly supported by the American Association for Cancer Research and Conquer Cancer. “The work enabled by my award was instrumental in revealing what needed to be done moving forward,” she said.
U.S. News & World Report, July 9, 2018
Fred Hutch researcher Dr. Christina Baik said there currently is no genetic screening test to predict risk of developing lung cancer, but several biomarkers are being studied and exploited to provide targeted treatments and improved outcomes once the disease is diagnosed.
Cancer Network, July 9, 2018
Dr. Nancy E. Davidson, Fred Hutch senior vice president and president and executive director of the Hutch’s clinical care partner Seattle Cancer Care Alliance, was on an expert panel of the American Society of Clinical Oncology that generated the organization’s latest treatment guidelines for HER2-positive breast cancer. The new guidelines, based on a review of 622 articles, are relatively unchanged from those of 2014, but they address timing and sequence of therapies.
U.S. News & World Report, July 4, 2018
Dr. Amanda Phipps provided comment in this story, examining the links of sleep and cancer. Phipps notes “from a biological perspective, there are a lot of good reasons for us to suspect that insufficient sleep, chronic sleep debt or short sleep duration could have an impact on the development of cancer."
GeekWire, July 2, 2018
Fred Hutch researchers led by Dr. Matthias Stephan used nanoparticles to deliver two drugs directly into solid tumors to shut down the tumors’ defense mechanisms and rally the immune system. Although this was a preclinical study, not done in human patients, it opens the possibility that chimeric antigen receptor (CAR) T-cell therapies could be used not just in blood cancers but also in solid tumors. The drugs would precondition the patient and the tumor so the T cells would work better, Stephan said.
Managed Care, July 2, 2018
This article published by Managed Care, focuses on the “Community Cancer Care in Washington State: Quality and Cost Report” recently released by the Hutch’s health care economics group, HICOR. “Committing to transparency as a catalyst for improvement, 27 hospital systems and cancer centers across Washington State bare all in the first public report to integrate clinic-level quality and cost data in oncology,” the article said.
Built in Seattle, July 2, 2018
Changes to the Fred Hutch board of trustees were noted in this list of major area tech hires in June. Matt McIlwain becomes chair, replacing Gov. Christine Gregoire, who remains on the board. Allan Jones of the Allen Institute, and Brian Jones, of Lyft, join. “The moves represent the Hutch’s recognition of tech as a key to future medical research,” according to the article.
Reader’s Digest, June 28, 2018
This story cited Fred Hutch research showing that women who kept food journals were more like to lose weight.
ScienceNews, June 27, 2018
“I think this is an incredibly exciting time,” said the Hutch’s Dr. David Maloney in an article on scientists’ efforts to build more effective, safer chimeric antigen receptor (CAR) T cells. CAR T-cell therapy produces promising results, but it can have serious side effects. Fred Hutch researchers lead studies to understand and mitigate these events.
Healio, June 26, 2018
Drs. Jeffrey Schouten and Thomas Uldrick were i interviewed for a cover story on HIV and cancer for Healio’s HemOnc Today. “How to prevent cancer in people with HIV and oncogenic viral infections, and how to diagnose the resultant cancers early so that treatment outcomes are improved, are important issues that need to be addressed for patients,” Schouten said.
GeekWire, June 26, 2018
Fred Hutch physician-scientist Dr. Eric Holland, senior vice president and director of the Human Biology Division, led a study that found that a subset of brain cancers called ependymomas can be traced back to a single, catastrophic mutation in a patient’s DNA. “It looks like a region of the DNA blew up,” he said. The GeekWire story also was reported on KIRO-TV.
The Washington Post, June 25, 2018
The Washington Post republished an article from The Conversation in which a bioethics and genomics expert urges caution for women considering genetic testing to assess breast cancer risk. Katherine Drabiak quoted Fred Hutch research saying that up to one-third of cancer-related deaths are due to obesity and sedentary lifestyle.
Healthline, June 25, 2018
Commenting on new clinical trials of saliva tests to identify men at risk for prostate cancer, Dr. Heather Cheng, a Fred Hutch prostate cancer researcher, said, “Saliva testing for better understanding of inherited risk for cancer is another good option, along with blood testing, and may help men learn vitally important information that can be helpful for medical decision-making with their doctors.”
Las Vegas Review-Journal, June 23, 2018
Jane Ann Morrison, a columnist with the Las Vegas Review-Journal, told readers that her 88-year-old father, Jim Morrison, a retired Boeing engineer who was diagnosed with non-Hodgkin lymphoma in 1991, was honored as a Hutch Hero at a June 14 Seattle Mariners game. “His bone marrow transplant at the center in 1993 has given my dad 25 additional years (and I predict even more),” she said.
The Daily Mail, June 21, 2018
The U.K. newspaper Daily Mail, Yahoo! UK, ABC News Australia and other sites carried an article about Fred Hutch research published in the American Journal of Obstetrics and Gynecology suggesting that red meat intake increases estrogen levels, which can lead to endometriosis.
MedPage Today, June 20, 2018
Two studies published in the Journal of Clinical Oncology suggest that many cancer drugs are reaching the market more quickly through the Food and Drug Administration’s breakthrough therapy designation program, but some are associated with higher rates of later safety questions. Gary Lyman, co-director of the Hutch’s outcomes and health economics group, co-authored an accompanying editorial, saying, “the FDA needs to first and foremost protect patients from serious adverse drug effects while it provides reasonable and timely access to promising new therapies for life-threatening conditions.”
Medscape, June 20, 2018
Dr. Gary Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research, was interviewed for a Medscape article about the American Society of Clinical Oncology’s endorsement of certain alternative therapies for women undergoing breast cancer treatment. “We know that the vast majority of cancer patients, particularly breast cancer patients, are using some type of alternative medicines. They may be taking supplements, doing yoga, getting massage therapy or acupuncture, but most doctors don’t talk about it,” said Lyman, who co-chaired the expert panel that recommended the endorsement.
Los Angeles Times, June 19, 2018
Mike Leum, an assistant director for the Los Angeles County Sheriff’s Department, raised $7,000 to climb Mount Hood with his son on June 10. They carried colorful flags with the names of cancer patients or survivors, and donated the money to Fred Hutch for cancer research.
CNN, June 19, 2018
Dr. Anne McTiernan, a Fred Hutch cancer prevention researcher, commented on new research about alcohol consumption and cancer risk. McTiernan, who was not involved in the study, said “alcohol increases risks for many cancers, including breast, colorectal, esophagus, liver, head and neck, and stomach.” The article appeared online at KTLA-TV, KVVU-TV, azfamily and other outlets.
Everyday Health, June 18, 2018
Dr. Benjamin O. Anderson, a breast cancer surgeon and Fred Hutch epidemiologist, was quoted in Everyday Health about a study showing that many breast cancer patients fail to receive recommended follow-up mammograms.
Nature, June 15, 2018
In a new approach to metastatic cancer, many researchers are targeting dormant malignant cells that later give rise to new tumors, according to the science journal Nature. Fred Hutch geneticist Dr. Jason Bielas is working to “barcode” rogue cells using specific DNA sequences. “Those cells can then be identified using cheap DNA-detection methods at a resolution of one in one billion cells.”
Seattle Times, June 15, 2018
Four days after the Hutch’s lease of the historic Lake Union steam plant was announced, real estate developer William Justen recounted the deal’s three-decade history.
Everyday Health, June 14, 2018
Dr. Heather Greenlee, a Fred Hutch specialist in naturopathic medicine and integrative therapies, explained new guidelines adopted by the American Society of Clinical Oncology on the use of certain integrative approaches for managing symptoms and side effects of breast cancer treatment. She is a co-author of an article announcing the guidelines in the Journal of Clinical Oncology.
GeekWire, June 12, 2018
GeekWire and Becker’s Hospital Review noted that David H. Browdy will become vice president and CFO on Aug. 1, replacing Randy Main, who is retiring after 30 years. Browdy recently served as Salt Lake City-based University of Utah’s associate vice president and CFO for health sciences.
GeekWire, June 11, 2018
Fred Hutch has signed a 10-year lease for the historic Seattle City Light Lake Union Steam Plant, which has housed a biotherapeutic company. Dr. Gary Gilliland, Fred Hutch president and director, said having world-class lab space already onsite saves Hutch time that a build-out would take. The story received wide coverage at The Seattle Times, KING-TV, KOMO-TV, KIRO-TV, KIRO-AM, KOMO-AM, Puget Sound Business Journal, The Registry (Puget Sound Real Estate), Seattle P-I, Seattle Daily Journal of Commerce, Curbed, and numerous online sites.
GeekWire, June 8, 2018
New Fred Hutch Board of Trustees chair Matt McIlwain and Fred Hutch COO Steve Stadum talk about the intersection of cancer research and technology. The story also notes the new additions of board members Allan Jones, president and CEO of the Allen Institute, and Lyft CFO Brian Roberts, a former high-ranking Microsoft executive.
Puget Sound Business Journal, June 7, 2018
“The HIV epidemic is global and our research works to make sure our solutions reach those most vulnerable,” said Steven Wakefield, president of the Pride Foundation in a feature profile. Wakefield is external relations director for the HIV Vaccine Trial Network that is headquartered at the Hutch, where he established The Legacy Project to increase racial and ethnic involvement in clinical trials.
U.S. News & World Report, June 6, 2018
Dr. Seth M. Pollack, a sarcoma expert at Fred Hutch, talks about the potential for – and the challenges in – creating vaccines to treat and prevent cancer. “There almost certainly is not a universal target. The vaccine has to tell the immune system to go find something specific, but there’s nothing specific that the immune system can look for that is common to all cancers,” he said, adding that “there are some targets that are expressed by lots of cancers.”
KING-TV, June 6, 2018
Dr. Jennifer Specht, a Fred Hutch breast cancer researcher, appeared live on KING 5's "Take Five" news show to provide expert commentary on a new breast cancer treatment study.
KING-TV, June 5, 2018
As part of a campaign to raise funds to fight cancer, 17-year-old Emily Chapman got a buzz cut on TV and raised nearly $3,400 for Fred Hutch research.
STAT News, June 4, 2018
Commenting on a study published in Nature Medicine, in which an experimental immune-based treatment appears to have cured advanced, metastatic breast cancer, Hutch immunotherapy researcher Dr. Josh Veatch said the results are intriguing but preliminary, and scientists do not fully understand why tumor infiltrating lymphocytes don’t eradicate cancer on their own.
KOMO-TV, June 4, 2018
Research presented at the American Society of Clinical Oncology (ASCO) and published in the New England Journal of Medicine suggests that new genetic testing may make it possible for 70 percent of early-stage breast cancer patients to avoid chemotherapy. Fred Hutch’s Dr. Kevin Cheung explained the study and its implications for patients.
AARP Magazine, June 2, 2018
Dr. Gary Lyman, co-director of the Hutch’s health economics group, HICOR, was quoted extensively in an AARP article on financial toxicity associated with cancer treatment. “Recent studies we’ve done have shown high rates of bankruptcy among patients with cancer. And this has escalated over the past decade, as some of the exciting new agents that have come along have just skyrocketed,” he said.
Reuters, June 1, 2018
Reuters is one of several sources to cover a Fred Hutch study presented at the annual meeting of the American Society of Clinical Oncology (ASCO). The study found that “colon cancer drugs cost twice as much in the United States as in Canada, but added expense does not translate to longer survival.” CNN, WebMD, GeekWire, MedPage Today, Medscape and other outlets also provided coverage. Dr. Veena Shankaran and Dr. Todd Yezefski from the Hutchinson Institute for Cancer Outcomes Research (HICOR) are quoted in the stories.
GeekWire, May 31, 2018
The ride-sharing service Lyft announced that Fred Hutch will be the first Seattle organization to join its Round Up & Donate program. Riders can round their fare up to the nearest dollar, donating the difference to the charity of their choice. Kelly O’Brien, Fred Hutch vice president of Philanthropy, said, “We are thrilled that Lyft made Fred Hutch a priority. Lyft passengers can turn every ride into fuel for cancer research because every day we are working to cure cancer faster.” The news was also covered by The Puget Sound Business Journal, and KOMO News.
The Wall Street Journal, May 28, 2018
Fred Hutch’s Dr. Stephanie Lee and Dr. Colleen Delaney are quoted in a feature story on companies striving to make bone-marrow transplants safer. Delaney explained an experimental therapy called NLA101 that was developed at Fred Hutch and then spun out as the company Nohla Therapeutics. Delaney is director of Fred Hutch’s cord-blood transplant program and founder and chief medical officer at Nohla. In mid-May, GeekWire and Puget Sound Business Journal reported that Nohla had closed a $45 million funding round, supporting its off-the-shelf cell therapies.
Puget Sound Business Journal, May 25, 2018
Fred Hutch’s annual Premier Chefs Dinner brought in a record $1.47 million. The PSBJ story notes that the featured chef, Robin Leventhal, told the crowd of her own experience with lymphoma.
Journal of Clinical Pathways, May 25, 2018
Following earlier coverage by several outlets on the release of the Hutch’s Community Cancer Care in Washington State: Quality and Cost Report, the Journal of Clinical Pathways conducted a Q&A with Dr. Gary Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research. “To our knowledge, this is the first time anything like this has been done in the United States,” he said.
CURE, May 25, 2018
Several outlets covered findings from the National Comprehensive Cancer Network showing that many breast cancer survivors are not receiving the recommended number of mammograms following surgery. Dr. Benjamin O. Anderson, of Fred Hutch and vice-chair of the NCCN’s breast cancer guidelines panel, said, “This lack of imaging follow-up represents a missed opportunity for identifying recurrent or new breast cancers among a high-risk patient subgroup.”
U.S. News & World Report , May 24, 2018
Dr. Marian L. Neuhouser, head of the Cancer Prevention Program at Fred Hutch, discussed possible links between soy products and breast cancer. She noted compounds found in soybeans and other plants can mimic the effects of estrogen, a prime driver of most breast cancers, but most studies have found no negative association between soy consumption and breast cancer risk.
KOMO News, May 23, 2018
KOMO News, GeekWire, KING-TV, KIRO-TV and other outlets covered the achievement of Seattle biotech writer Luke Timmerman, who reached the peak of Mount Everest on May 22 in his quest to raise funds for cancer research at Fred Hutch. Coverage continued through early June with interviews with Timmerman and recaps of his expedition on KING-TV, KOMO News, and KATU-TV. He has raised about $340,000 so far.
The Associated Press, May 22, 2018
In an Associated Press story on the financial toll that cancer treatment can take, Fred Hutch’s Dr. Veena Shankaran, of the Hutch’s health economics group, HICOR, spoke about the financial struggles faced by cancer patients. She said, “A lot of times people don’t realize there are resources available until they’ve already gone broke.” The story appeared in the Chicago Tribune, The Seattle Times, at CBS News online and in numerous other outlets.
Medscape, May 20, 2018
A new study appears to be a turning point for the prostate cancer prevention drug finasteride. Previous study findings suggested there may be a link between use of the drug and a more lethal form of prostate cancer, but long-term follow-up shows that is not true. Phyllis Goodman, a biostatistician at Fred Hutch, is noted for her “laborious work” on the project.
The Seattle Times, Pacifici NW Magazine, May 17, 2018
Dr. Gary Gilliland, president and director, and others at Fred Hutch are quoted in an in-depth feature on the institution’s history and day-to-day work, especially in cancer immunotherapy. “We’re curing people. The question is: Why aren’t we curing everybody, and how do we extend those curative methods to other types of cancers that have been more recalcitrant?” Gilliland said. The magazine also published a story behind the story. Coverage was picked up by Tacoma’s News Tribune and other outlets.
Precision Vaccinations, May 15, 2018
Dr. Stephen de Rosa was quoted about promising results seen in a Phase I clinical trial of Inovio Pharmaceuticals’ PENNVAX-GP, an experimental vaccine against HIV. The study was supported by the National Institutes of Health and the HIV Vaccine Trials Network, headquartered at Fred Hutch.
OncLive, May 14, 2018
Dr. Laura Panattoni, of the Hutchinson Institute for Cancer Outcomes Research (HICOR), is quoted on reasons why cancer patients have high visits to the emergency department.
GeekWire, May 10, 2018
Gary Gilliland, president and director of Fred Hutch was named “Geek of the Year” at the 2018 GeekWire Awards presentation. In selecting Gilliland for the prestigious award, GeekWire noted, “The nationally recognized cancer center is working on some of the hottest frontiers in cancer research, namely cellular immunotherapy treatments that specifically target a patient’s unique cancer mutations. Under Gilliland’s leadership, the Hutch has recruited big names from the technology field to its board of trustees, including Microsoft CEO Satya Nadella and Mike Clayville, a vice president at Amazon Web Services.” Mentioned as one of the most touching moments of the evening was when Gilliland asked his fellow nominees to share the stage with him.
NPR, May 9, 2018
A 3D model of a living human cell – the newly unveiled Allen Integrated Cell – could help scientists solve many medical mysteries. Fred Hutch molecular biologist Roger Brent, who has been using the tool for several months, said, “This lets you see things with a simple microscope that are going to be helpful to researchers all over the world – including in less affluent places.”
Los Angeles Times, May 8, 2018
Ruth Etzioni, a biostatistician in the Public Health Sciences Division, commented on prostate cancer screening recommendations issued by the U.S. Preventive Services Task Force on how men can judge whether testing is right for them. “It means the benefits and harms of the decision are going to be different for different people. Screening might be a good decision for you, but your friend may come up with a different decision, she said. The LA Times article also appeared in The Seattle Times and other outlets.
GeekWire, May 7, 2018
Fred Hutch and Microsoft are working together to reduce the side effects of chemotherapy and the emergency room visits that result. “They’ve unveiled a new pilot program that will leverage Microsoft’s artificial intelligence technology and Fred Hutch’s clinical and data science expertise,” said a story in GeekWire. The story also appeared on KIRO-TV.
The Seattle Times, May 4, 2018
The Seattle Times noted that landmarks across Seattle would glow orange for several nights during the week of May 7 to bring attention to Fred Hutch’s annual Obliteride bike ride that raises money to fight cancer. The event, which will be on Aug. 11, has brought in $12 million since it started. The story also was covered by KZJO-TV, KING-TV, KOMO-TV and KCPQ-TV.
The Spokesman-Review (Spokane), May 3, 2018
Dr. Scott Ramsey, director of the Hutchinson Institute for Cancer Outcomes Research, said the organization’s recently released study – the Community Cancer Care in Washington State: Quality and Cost Report – said the document is a first step toward improving the quality of cancer care across the state. “Every one of these cancer providers does things well and also has areas where they need to improve,” he said in an article about providers in the Spokane area.
Puget Sound Business Journal, May 3, 2018
Dr. Gary Gilliland, Fred Hutch president and director, was quoted in an article about the release of the Community Cancer Care in Washington State: Quality and Cost Report. “Participants in this endeavor can use it to learn where their efforts to improve quality and control costs are working most efficiently, and where they are not,” he said in a blog post, according to the article. The Hutchinson Institute for Cancer Outcomes Research worked on the report for five years, collecting data in partnership with providers and insurers.
GeekWire, May 2, 2018
GeekWire reported that Hutch spinout SEngine Precision Medicine and its research partners – Fred Hutch and the Oregon Health and Science University – received a $3.1 million boost from the National Institutes of Health. Recognizing that every patient’s cancer is unique, SEngine has an experimental test “that grows and analyzes a patient’s cancer cells to figure out which drugs will work best for them,” the article says.
Forbes, May 1, 2018
Fred Hutch ranked No. 24 on Forbes’ list of the top 500 companies with 1,000 to 5,000 employees. The rankings were based on confidential, 30-question employee surveys. Fred Hutch was one of 10 organizations listed in the “health care and social” category.
Medscape, April 26, 2018
Data presented by Dr. Cameron Turtle, immunotherapy researcher in the Clinical Research Division, was included in a Medscape article for treatment professionals on serious toxicities that may occur with the use of immunotherapy called chimeric antigen receptor (CAR) T cells.
OncLive, April 26, 2018
Providing background on new guidelines issued by the American Society of Clinical Oncology, Dr. Gary Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research, said biologic therapies can be effective in fighting cancer, but they often are costly. As some biologic patents expire, “other companies are seeing an opportunity to develop similar biologic therapies and get them approved to compete.” Lyman, a member of the ASCO board of directors, was lead author of the organization’s statement.
GeekWire, April 23, 2018
The Seattle Partnership for Research on Innovative Therapies, or SPRInT, an alliance between Fred Hutch, the University of Washington and Japan-based Takeda Pharmaceutical Company Ltd., was named one of five finalists for GeekWire’s Newcomer of the Year award. GeekWire readers were invited to vote.
FierceBiotech, April 20, 2018
FierceBiotech and other outlets reported on a study published by Drs. Christopher Peterson and Hans-Peter Kiem of the Fred Hutch Clinical Research Division about a gene editing technique studied in non-human primates that may one day help fight HIV in people.
GeekWire, April 19, 2018
The Chan Zuckerberg Initiative announced a new infusion of funding in support of scientists working on the Human Cell Atlas, including Fred Hutch researcher Raphael Gottardo, a member of the Vaccine and Infectious Disease Division and the Public Health Sciences Division. The project to map every cell in the human body is part of the $3 billion Chan Zuckerberg Initiative, the philanthropic organization of Facebook founder Mark Zuckerberg and his wife Priscilla Chan, according to GeekWire.
Nature.com, April 17, 2018
An article on circadian rhythm and the timing of drug delivery referenced research by Dr. Eric Holland, who leads the Human Biology Division at Fred Hutch. His work “has shown that corticosteroids can reduce the effectiveness of radiation therapy in humans and that there are optimal times to administer radiation in mice,” the story said.
Xconomy, April 16, 2018
An article on the development of advanced immunotherapies to treat lung cancer – possibly even sidestepping the need for chemotherapy – described a new measure, called tumor mutational burden, that is emerging as a way to predict which patients may respond well to immunotherapy. Dr. Gary Lyman, health economist and oncologist at Fred Hutch, comments on the work.
Healio, April 14, 2018
The American Association for Cancer Research announced that Dr. Gary Gilliland, Fred Hutch president and director, has been elected a fellow of the AACR Academy, a recognition of contributions “to significant innovation and progress against cancer.”
The Lancet, April 13, 2018
In an obituary in The Lancet, Dr. Gary Gilliland, Fred Hutch president and director, and Dr. Garnet Anderson, senior vice president and director of the Public Health Sciences Division, commented on the vision and leadership of Dr. Robert Day, Fred Hutch president and director from 1981 to 1997. Day moved the Hutch to its current location and oversaw the creation of the Seattle Cancer Care Alliance.
Health.com, April 12, 2018
This article on spring being a good time to lose weight mentions a Fred Hutch study showing that certain people lose weight when they add a vitamin D supplement.
MIT Technology Review, April 11, 2018
Dr. Hans-Peter Kiem, a Fred Hutch oncologist, stem cell and gene therapy researcher, is quoted in this story about the gene-editing tool CRISPR, which may allow doctors to cure some diseases by altering a patient’s DNA. “Since monkeys are so similar to humans, I don’t think there’s going to be a huge challenge in translating this work to humans,” he said.
GeekWire, April 10, 2018
Dr. Jay Mendoza has been named director of the Fred Hutch Health Disparities Research Center and associate director of two related programs. “In the roles, Mendoza will lead cancer outreach and education efforts in much of Western Washington with the goal of improving cancer-related public health efforts in the region,” GeekWire said.
The Seattle Times, April 10, 2018
Jeanette Woldseth, who became Washington’s first paid female firefighter when she joined the Bellevue Fire Department in 1977, died in February after a battle with cancer. The Seattle Times said Woldseth, who started biking several years ago to participate in Fred Hutch’s annual Obliteride, raised $51,000 for research over the years.
The Seattle Times, April 10, 2018
The Seattle Times editorial board said the Rev. Dr. Samuel B. McKinney, the longtime pastor of Mount Zion Baptist Church and civil rights leader who died April 7, was “a giant.” Noting that McKinney served on the boards of many organizations including the Fred Hutchinson Cancer Research Center, the article said, “McKinney was a man of conscience and integrity, widely respected throughout the Greater Seattle area for his work in many realms, from civil rights to economic justice to education to interfaith relations.”
Cancer Therapy Advisor, April 9, 2018
A new study found that men who took finasteride for seven years had reduced risk for prostate cancer throughout 16 years of follow-up. “One concern with these kinds of interventions is that while people are taking the intervention that prostate cancer may be prevented, but then rates snap back once the intervention is discontinued. That did not happen here. The preventive benefit of finasteride was maintained over the 16 years,” said Dr. Joseph Unger, assistant member of the Cancer Prevention Program.
INSIDER, March 28, 2018
A story that went viral in 2017 launched a wave of inaccurate stories about women acquiring male DNA from sexual partners. Not true, said Dr. J. Lee Nelson, a Fred Hutch autoimmunity researcher and rheumatologist. She explained that the most common source of male DNA in adult women is from prior pregnancy with a male child and how the mixing of DNA could benefit health.
KING-TV, March 28, 2018
In final preparation for his March 27 departure to Nepal to climb Mount Everest, biotech journalist Luke Timmerman told KING-TV that his biggest concern was leaving his family for the 10-week adventure. Timmerman has raised more than $328,000 for cancer research at Fred Hutch, and his progress has been followed by GeekWire, area TV and radio stations and other outlets.
Healio, March 27, 2018
Dr. Paul Nghiem, a dermatologist and affiliate investigator at Fred Hutch, talked with Healio’s Hem/Onc Today about the rapid increase in incidence of Merkel cell carcinoma. Nghiem and colleagues expect this aggressive skin cancer’s incidence to “continue to increase through 2025 because of the strong link between risk and advancing age.”
AJMC, American Journal of Managed Care, March 26, 2018
The American Journal of Managed Care reported on a presentation by Fred Hutch’s Dr. John Thompson on immune-related adverse events that can occur with the use of immune checkpoint inhibitors. “With the good news has come some not so good news,” he said at the annual conference of the National Comprehensive Cancer Network.
Smithsonian.com, March 23, 2018
Dr. Keith Jerome, a virologist at Fred Hutch, co-authored a 2016 study about gene editing in herpes-infected mice. “His is the first study to show that gene-editing technology can reach the latent virus in a nerve cell, and the first to use that technology to damage some of the virus’ DNA,” according to a Smithsonian.com article on this and other efforts to combat the virus in humans.
Seattle Business magazine (seattlebusinessmag.com), March 23, 2018
In a commentary in Seattle Business magazine, Chrissy Glaister, the lead usability engineer at Product Creation Studio in Seattle, spotlighted Fred Hutch spinout 2Morrow as one of the local companies developing lifestyle-improvement apps. “The company’s programs were created in collaboration with – and based on research by – Jonathan Bricker from Fred Hutchinson Cancer Research Center,” she said.
Cancer Therapy Adviser, March 22, 2018
Dr. Ruth Etzioni, a biostatistician in Fred Hutch’s Public Health Sciences Division, discussed recent studies showing that African-American men with prostate cancer tend to have significantly worse survival outcomes than white men. Research indicates the cancer grows more rapidly in black men, but Etzioni said timing of screenings, quality of surgical centers and other factors need to be considered.
Puget Sound Business Journal, March 21, 2018
Dr. Gary Gilliland, Fred Hutch president and director, said the Amazon-JPMorgan Chase-Berkshire Hathaway partnership aimed at driving down health care costs could help change the industry for the better, but it won’t be easy because this is new territory for the companies and there are many complexities to confront.
The Atlantic, March 21, 2018
Centromeres are a specialized region on chromosomes, and malfunctioning centromeres have been linked to disorders and diseases like cancers. An Atlantic article on researchers working to put together the last missing pieces of the human genome quotes geneticist Dr. Steve Henikoff, who studies centromeres at Fred Hutch. “If you want to look at a human variation, I think this is the place to look,” he said.
Healio, March 20, 2018
Dr. Kedar Kirtane, a fellow in the Hematology/Oncology Fellowship Program at Fred Hutch discussed a retrospective study he and colleagues conducted that found that racial minorities with blood cancers had lower rates of advance directives and received significantly more aggressive care than white patients. Kirtane said providers need to do a better job of discussing palliative care and advanced care planning, especially for historically disadvantaged groups.

Mt. Zion Baptist Church and Fred Hutch host Black History Month Gathering
KZJO-TV, Q13 news in the morning, Feb. 25, 2018
Q13 News in the Morning summarized a Feb. 24 Black History Month event: “Dozens gathered in celebration of Black History Month at a local church in Seattle yesterday. The focus was on resilience and strength through building community. Mount Zion Baptist Church hosted the event along with representatives from Fred Hutch Diversity Council. Keynote speakers included Seattle’s interim police chief and other local leaders.”

Herald.net, Feb. 24, 2018
Leslie Tidball, 64, is lead prosecutor for the city of Everett, a lifelong athlete who took up ice skating 15 years ago and a founder of the Snohomish County Women’s Ice Hockey team, according to a HeraldNet feature story. “On Aug. 9, 2015, she summited Mount Rainier to benefit the Fred Hutchinson Climb to Fight Breast Cancer. She climbed 14,411 feet in honor of her mother, now 89, who is a five-year breast cancer survivor,” the article reports. “She raised over $7,000 and reached the mountaintop in three days.”
Redmond Reporter, Feb. 23, 2018
Firefighters from the Redmond Fire Department will participate in the 27th Annual Scott Firefighter Stair Climb March 11 at the Columbia Center in Seattle. The fundraiser attracts firefighters from around the world and raises money for the Leukemia and Lymphoma Society, which locally funds research at Fred Hutch, according to the Redmond Reporter.
Healio, Feb. 22, 2018
Dr. Rachel B. Salit, assistant member of the Clinical Research Division, reported on a clinical trial using a new drug, ruxolitinib (Jakafi) before stem cell transplantation in patients with myelofibrosis, a serious bone marrow disorder. According to this Healio article, the drug appeared safe and aided in the prevention of cytokine release syndrome, which can produce life-threatening systemic symptoms.
Targeted Oncology, Feb. 22, 2018
Dr. David Maloney, a member of the Fred Hutch Clinical Research Division, in an interview with Targeted Oncology, talked about a chimeric antigen receptor (CAR) T-cell therapy directed against a specific antigen, CD19, in patients with diffuse large B-cell lymphoma. “By being able to give the T cells in a defined mixture of CD4 and CD8 cells, we get a better relationship between the dose response and the dose toxicity,” he said.
FierceBiotech, Feb. 22, 2018
Japanese drugmaker Takeda has teamed up with Fred Hutch and the University of Washington to focus on developing drugs to treat cancer, gastrointestinal disease and neurological disorders. The collaboration is dubbed The Seattle Partnership for Research on Innovative Therapies, or SPRInT.
Medscape, Feb. 22, 2018
Asked to comment on a new study about targeted drugs for chronic myeloid leukemia, Fred Hutch’s Dr. Jerald Radich said the newer-generation nilotinib is probably better than the first-generation drug for achieving a deep and lasting response, but it has more cardiovascular complications, is more expensive, and there are no clear long-term survival differences. Radich, chair of the National Comprehensive Cancer Network CML Guidelines Committee, was not involved in this study, but has participated in others. The Reuters Health story ran in Medscape and other outlets.
Cancer Network, Feb. 21, 2018
Black men have had much higher mortality rates from prostate cancer than white men, but that disparity appears to have narrowed since the widespread adoption of prostate-specific antigen (PSA) screening in the 1990s. Dr. Ruth Etzioni, biostatistician in the Public Health Sciences Division, led a study finding that the narrowing of disparities is not as significant as believed.
Puget Sound Business Journal, Feb. 21, 2018
The Puget Sound Business Journal selected the Allen Institute for Brain Science, launched in 2003 by Microsoft co-founder Paul Allen, as Innovator of the Year. “If you want to pick an organization that would truly be identified as on the cutting edge of innovation, boy they're it,” said Fred Hutchinson Cancer Research Center President and Director Dr. Gary Gilliland. “We all benefit from the fact that they do this as an open-sourced approach.” Fred Hutch was Puget Sound Business Journal’s Innovator of the Year in 2017.
CNN, Feb. 21, 2018
In a CNN story that appeared in numerous outlets, Dr. Seth Pollack, assistant member of the Clinical Research Division, commented on personalized cancer vaccines, a form of immunotherapy. Pollack spoke about the evolving science of cancer vaccines and how they’ve shown promise in treating some types of sarcoma.
GeekWire, Feb. 21, 2018
Seattle startup 2Morrow Inc. released a pain management app based on the same scientific foundations of its earlier apps for smoking cessation and weight loss. “Fred Hutchinson Cancer Research Center clinical psychologist Jonathan Bricker, whose work formed the basis for 2Morrow’s smoking cessation app, described in a past interview how app staples like push notifications and gamification can keep users engaged and encourage them to stick to their treatment plan,” said a GeekWire story.
The Seattle Times, Feb. 20, 2018
Regarding ongoing debates about the potential health benefits of cocoa, The Seattle Times mentioned a study being conducted by Fred Hutch and Brigham and Women’s Hospital: “COSMOS, or COcoa Supplement and Multivitamin Outcomes Study, is investigating whether taking daily supplements of 600 mg of cocoa flavanols or a common multivitamin reduces the risk for developing heart disease and stroke, as well as cancer.”
OncLive, Feb. 20, 2018
Dr. David Maloney, medical director of cellular immunotherapy at Fred Hutch, participated in an OncLive discussion for researchers and clinicians on JCAR017, a chimeric antigen receptor (CAR) T-cell immunotherapy in clinical trials for B-cell Non-Hodgkin lymphoma. Maloney said clinical trial leaders have reported “very encouraging activities.”
Cure, Feb. 20, 2018
Dr. John A. Thompson, a member of the Clinical Research Division, was quoted in a curetoday.com article about new guidelines released by the National Comprehensive Cancer Network and the American Society of Clinical Oncology to help patients and health care teams understand and manage immunotherapy-related toxicities, particularly with checkpoint inhibitors. Thompson was a leader on both organizations’ panels developing the guidelines.
Seattle Business Magazine, Feb. 19, 2018
Seattle Business Magazine article describes progress by SEngine, founded in 2015 as a Fred Hutch spinoff, in identifying which cancer drugs will likely work based on the DNA of a patient’s cancer.
GeekWire, Feb. 18, 2018
A GeekWire story reported that former Vice President Joe Biden said in a speech to the American Association for the Advancement of Science that the U.S. should be dramatically increasing investments in research and noted research at Fred Hutch and other Seattle institutions for advancements in treating cancer.
ASCO Cancer.net, Feb. 14, 2018
Dr. Gary H. Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), presented a cancer.net podcast to help patients understand “biosimilars,” drugs that are created to be very similar to existing biological treatments. Lyman was the lead author of a position statement on biosimilars in cancer treatment, released Feb. 14 by the American Society of Clinical Oncology (ASCO).
NBC local affiliate in Florida, Jan. 18, 2018
Hutch researchers Dr. Irwin Bernstein and Dr. Soheil Meshinchi talked about a drug developed at Fred Hutch. Mylotarg made its debut in 2000, but was taken off the market 10 years later. Now it’s back, and patients with a certain form of acute myeloid leukemia are showing a 35 to 40 percent increase in survival.
The Cancer Letter, Jan. 12, 2018
In a tribute, Dr. Gary Gilliland talked about working with Dr. Robert W. Day and the last accomplishments the former president made, including moving the Fred Hutch campus to its current location in South Lake Union.
The Atlantic, Jan. 12, 2018
Biologist Dr. Harmit Malik, of the Fred Hutch Basic Sciences Division, was quoted in a story in The Atlantic about Arc, a difficult-to-study gene that looks like a virus and influences learning and memory, apparently by helping neurons share genetic information among themselves.
Reuters, Jan. 9, 2018
Commenting on a study about racial and socioeconomic health care disparities among elderly patients with lung cancer, Fred Hutch’s Dr. Veena Shankaran said cultural and community beliefs may play a role in treatment decisions, but “many studies have shown that black patients have less access to cancer care and worse cancer outcomes than whites.”
The Seattle Times, Jan. 4, 2018
Microsoft will partner with Adaptive Biotechnologies, which was formed in 2009 with Fred Hutch technology, to develop blood tests that will “alert doctors when people are fighting specific diseases.
STAT, Jan. 1, 2018
Hutch epidemiologist Dr. Noel Weiss commented on a recent article in Annals of Internal Medicine suggesting that too much screening for certain cancers can skew our view of risk factors.
ASH Clinical News, Jan. 1, 2018
In an American Society of Hematology Q&A, Hutch president and director Dr. Gary Gilliland talks about the people and events that inspired him to become a doctor and specialize in hematology.
KIRO-TV, Jan. 1, 2018
In a story featuring Bridgette Hempstead, founder of the Cierra Sisters, a support group for black women with breast cancer, Dr. Nancy Davidson, senior vice president and director of the Clinical Research Division, said there is a common and false misconception that nothing can be done about a breast cancer diagnosis.